With the advancement of tissue specific microRNA delivery mechanisms and the expansion of literature on SALL4-targeting microRNAs in various cancer types, we propose that targeting SALL4 with microRNA-based therapeutics may be a new direction in overcoming SALL4 reactivation. Here, SALL4 is linked to cancer.